Loading this company
United Therapeutics Corporation
UTHRPrices in USD
TickerWorth ScoreB61/100
What we think
Priced within our range of $252.14 to $588.23.
Price
$533.12USD down −$8.39 (−1.55%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$252.14–$588.23
What the price needs: revenue growth of -0.5%/yr for 5 years (our model assumes 4.0%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $533.12Priced · Prices are delayed.
Is it a good business?
- Valuation67 out of 100
- Growth67 out of 100
- Financial health100 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$656.93 across 14 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in United States. The company employs roughly 1,400 people.
Key stats
52-week range$409.07–$609.35
- Open
- $545.49
- Day high
- $551.77
- Day low
- $530.18
- Previous close
- $541.51
- Volume
- 668,250 · 0.95× avg
- Average volume
- 701,668
- Market cap
- $22,865,885,184.00
- P/E (TTM)
- 19.09
- Earnings per share
- $27.92
- Beta
- 0.49
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Disclosed another material event
- Signed a material agreement
- Reported quarterly or annual results
- Changed leadership or its board
- Changed leadership or its board
- Reported quarterly or annual results
- Disclosed another material event
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- ROTHBLATT MARTINE AOption exercise · $1,118,720.00
- ROTHBLATT MARTINE AOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.